Merck Manual Fifteenth Edition, Berkow et al, eds, 1987, p. 1380.* |
Burstein et al., “Structure-Function of Muscarinic Receptor Coupling to G Proteins,” J. Biol. Chem., 270:3141-3146 (1995). |
Messier, T. L., et al., “High Throughput Assays of Cloned Adrenergic, Muscarinic, Neurokinin, and Neurotrophin Receptors in Living Mammalian Cells,” Pharmacol. Toxicol., 76(5):308-311 (1995). |
Faris, P.L. et al., “Nociceptive, but not Tactile, Thresholds are Elevated in Bulimia Nervosa,” Biol. Psychiatry 32:462-466 (1992). |
Schapira, M. et al., “The Current Status of Gastric Prokinetic Drugs,” Acta Gastroenterolog. Belg., 53:446-457 (1990). |
Dumuis et al., “The Gastrointestinal Prokinetic Benazmide Derivatives are agonists at the non-classical 5-HT receptor (5-HT4) Positively Coupled To Adenylate Cyclase In Neurons,” N.S. Arch Pharmacol., 340:403-410 (1989). |
Clarke et al., “The 5-HT4 Receptor: Naughty, But Nice,” Trends in Pharmacological Sciences, 10:385-386 (1989). |
Barnes et al., “Identification of 5-HT3 Recognition Sites In The Ferret Area Postrema,” J. Pharm. Pharmacol., 40:586-588 (1988). |
Meuldermans, et al., “Excretion and Biotransformation of Cisapride In Dogs and Humans After Oral Administration,” Drug Metab. Dispos., 16(3): 403-409 (1988). |
Meuldermans, et al., “Excretion and Biotransformatin of Cisapride in Rats After Oral Administration,” Drug Metab. Dispos., 16(3):410-419(1988). |
Costall B., et al., “Emesis Induced By Cisplatin In The Ferret As A Model For The Detection of Anti-Emetic Drugs,” Neuropharmacology, 26:1321-1326 (1987). |
Van Peer et al., “Clinical Pharmacokinetics of Cisapride,” Excerpta Medica, Current Clinical Practice Series, A.G. Johnson and G. Lux, Eds. Amsterdam. 48:23-29 (1988). |
Van Daele et al., “Synthesis of Cisapride, a Gastrointentestinal Stimulant Derived From Cis-4-Amino-3-Methoxypiperidine,” Drug Development Res., 8:25-232 (1986). |
Ebert, W. R., “Soft Elastic Gelatin Capsules: A Unique Dosage Form,” Pharm. Tech., 1(5):44-50 (1977). |
Shah, M., “Gastroesophageal Reflux—How to Mend it?” Indian J. Pediatr., 63:441-445 (1996). |
Blecker, U. et al., “The Role of “Occult” Gastroesophageal Reflux in Chronic Pulmonary Disease in Childre,” Acta Gastro-Enterologica Belgica, 58(5-6):348-352 (1995). |
Noor, N. et al., XP002128489, “Effects of Cisapride on Symptoms and Postcibal Small Bowel Motor Function in Patients with Irritable Bowel Syndrome,” Scandianavian J. Gastroent. 39(6):605-611 (1998). |
Ward, R.M. et al., “Cisapride: A Survey of the Frequency of Use and Adverse Events in Premature Newborns,” Pediatrics, 103(2):469-472 (1999). |
Vandenplas, Y., “Clinical Use of Cisapride and its Risk-benefit in Pediatric Patients,” Eur. J. Gastroent. Hepat. 10(10):871-881 (1998). |
Skinner, S., “Gastric Ulcer Presenting as Gastroesophageal Reflux and Apnea in a Term Neonate,” Tex. Medic., 94(9):57-58 (1998). |
Champion, M.C. and Orr, W.C., Evolving Concepts in Gastrointestinal Motility; W.C. Blackwell Science Ltd., Cambridge, MA; 1996, pp. 200-220. |